(1) IMGN has no inside ownership. This gives you an idea of how much management believes in their own company
(2) IMGN lives off of royalty which is pennies on the dollar compared to having their own product to sell rather than partnerships
(3) IMGN sold off its most lucarative revenue Kadcyla stream to put all their eggs into developing one product which has some obstacles to over come before reaching the market, meanwhile IMGN is flleecing investors to stay alive (Don't be surprised if IMGN down the road issue more shares causing dilution)
(4) As each day goes by, targeted therapy (which is what IMGN does) becomes more irrelvant as immunotherapy takes over the market
Play IMGN for the roller coaster ride but I don't see putting my retirement money on this stock.